Deutsche Bank analyst Justin Bowers maintained a Buy rating on IQVIA Holdings (IQV – Research Report) yesterday and set a price target of $290.00. The company’s shares closed last Thursday at $219.40.
According to TipRanks.com, Bowers is a 3-star analyst with an average return of 4.9% and a 42.9% success rate. Bowers covers the Healthcare sector, focusing on stocks such as Select Medical, LHC Group, and Amedisys.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $266.43 average price target, implying a 25.4% upside from current levels. In a report issued on April 18, Robert W. Baird also maintained a Buy rating on the stock with a $274.00 price target.
Based on IQVIA Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.64 billion and net profit of $318 million. In comparison, last year the company earned revenue of $3.3 billion and had a net profit of $119 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
North Carolina-based IQVIA Holdings, Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More on IQV:
- What Made Deutsche Bank Upgrade Discover Financial Services’ Stock?
- Analysts Are Neutral on These Consumer Goods Stocks: Ford Motor (F), Essity AB (ETTYF)
- Deutsche Bank Sticks to Its Buy Rating for Qualcomm (QCOM)
- Mastercard (MA) Received its Third Buy in a Row
- Amazon (AMZN): New Buy Recommendation for This Consumer Goods Giant